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Abstract
A kidney stone in a person with one kidney requires urgent attention which may result in
surgical and/or hospital attention. We conducted a matched retrospective cohort study to
determine if living kidney donors compared to healthy non-donors have a higher risk of: 1)
kidney stones with surgical intervention, and 2) hospital encounters for kidney stones. We
reviewed and linked information from pre-donation charts to Ontario healthcare databases.
We selected healthy non-donors from the general population, matching ten non-donors to
every donor, to generate a cohort of 2,019 donors and 20,190 non-donors. There was no
difference in the rate of 1) kidney stones with surgical intervention comparing donors to nondonors (8.3 vs 9.7 events/10,000 person-years; rate ratio[RR] 0.85; 95% confidence
interval[CI] 0.47-1.53), and 2) hospital encounters for kidney stones (12.1 vs 16.1
events/10,000 person-years; RR 0.75; 95% CI 0.45-1.24). These interim results are
reassuring for the safety of living kidney donation.
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Chapter 1: Introduction
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1.1

Background & Overview

Every year, over 27,000 individuals worldwide choose to undergo living kidney donation
to help someone in need (1). Knowledge of the long-term outcomes of living kidney
donors is required to maintain public trust in the transplantation system, inform the
choices of potential donors and recipients, and to guide the follow-up care necessary to
maintain optimal long-term health.
One outcome that remains poorly understood in past living kidney donors is the
subsequent development of kidney stones. In September 2012 we performed a detailed
search of bibliographic databases (Pubmed, Google Scholar) and found only a few
reports of living kidney donors being treated for kidney stones at the time of
nephrectomy. However, these studies did not report the rate or long-term risk of kidney
stones in this unique population. We expanded the search to include kidney stones in
those with a solitary kidney for any reason and again found only literature discussing the
management of the stone at the time of its occurrence.
In the general population, kidney stones are common with an estimated lifetime risk of
10-15% (2, 3). Most stones are small and pass through the urinary tract spontaneously
within four weeks of initial symptoms. However, some stones may require surgical
intervention including shockwave lithotripsy, ureteroscopy or percutaneous
nephrolithotomy (3, 4). There is no reason to suspect that living kidney donors would
have a higher risk of kidney stones than members of the general population. Yet, a kidney
stone in an individual with a solitary kidney can potentially obstruct the ureter, leading to
acute renal failure and may result in urgent hospital attention and even surgical
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intervention (5). This is also a concern because kidney stones can result in a decline in
renal function, and this risk may be even higher in donors compared to non-donors. We
conducted this matched retrospective cohort study to determine if living kidney donors
compared to healthy non-donors have a higher risk of: 1) kidney stones with surgical
intervention, and 2) hospital encounters for kidney stones.
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Chapter 2: Literature Review
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2.1 Kidney failure
End-stage renal disease (ESRD) or kidney failure is the result of complications from
reduced renal function, and is the most severe stage of chronic kidney disease (CKD) (6).
The best measure of renal function used to assess the severity of kidney disease is called
the glomerular filtration rate (GFR) (7). It represents an estimate of the amount of blood
filtered by the glomeruli in the kidney per minute. The GFR of a healthy individual is
typically around 90-120 mL/min per 1.73m2 (8). ESRD is characterized by either a
reduction in estimated glomerular filtration rate (GFR) to level below 15 mL/min per
1.73m2, or by the requirement of renal replacement therapy to prevent increased
morbidity and mortality (6).
The prevalence of end-stage renal disease or kidney failure is on the rise, with over one
million individuals affected worldwide. This number continues to increase by 7% per
year and in Canada alone the number of individuals living with end-stage renal disease
has tripled over the past two decades (9, 10). Patients with ESRD require some form of
renal replacement therapy in order to maintain life.
2.2 Renal Replacement Therapy
There are several different types of renal replacement therapy that can be used to treat
patients with kidney failure. Dialysis involves the use of an artificial filtration system to
clear the patient’s blood of toxic waste products. There are two main forms of dialysis.
The first and most common form of dialysis is hemodialysis, which involves taking blood
out of the patient’s body, filtering it through the dialysis machine and then pumping it
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back into the patient (11). Typically a patient has to receive hemodialysis multiple times
a week, with each treatment lasting 3-4 hours. The second form of dialysis is peritoneal
dialysis, which allows the filtration to occur within the patient’s body through the
introduction of fluid within the peritoneum. Waste products are filtered from the blood
across the peritoneum membrane, and the fluid is then flushed out of the peritoneal cavity
(11). Though the majority of patients with kidney failure are treated with dialysis, it is not
their best treatment option. Dialysis is associated with numerous complications, reduced
survival, and poorer quality of life when compared with transplantation (11-14).
Compared to dialysis, transplantation is the preferred treatment option for end-stage renal
disease resulting in 10 to 15 years longer survival (15). A systematic review of 110
studies comparing kidney transplantation to dialysis concluded that transplantation was
associated with significantly reduced mortality, reduced cardiovascular complications
and improved quality of life (16). As well, the magnitude of the improvement in health
with transplantation was found to increase over time (16).
There are two types of transplantation – deceased donation or living donation. Deceased
donation occurs after an individual dies as a result of brain death or cardiovascular
collapse. In this case, the individual either registered or expressed their wish to become
an organ donor prior to death (which is confirmed by family members of the deceased).
Unfortunately the number of deceased donations has not been sufficient enough to meet
the growing demand for organs. On the other hand, rates of living kidney donation are
rising in an attempt to address this demand. Living kidney donation involves a living
individual making the choice to donate one of their kidneys to someone in need.
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2.3 Living kidney donation
The first successful living kidney donation was performed by Dr. Murray in 1954
between identical twins (17). Since then there have been significant advancements in
transplant medicine and immunosuppression. Individuals who receive a kidney from a
living donor have better outcomes with longer graft survival than those who receive a
kidney from a deceased donor (18). The longer survival of a graft from a living kidney
donor can be attributed to the fact that the kidney can be removed from the donor and
transplanted into the recipient without delay. This minimizes the damage to the kidney
due to ischemia, or loss of blood flow (19).
A decision analysis of treatment options for patients with end-stage renal disease and
type I diabetes demonstrated that transplants from living kidney donors were associated
with 10.29 quality-adjusted life-years (QALY), while deceased donor transplants and
dialysis treatments were associated with 6.53 QALY and 4.52 QALY respectively (20).
Living kidney donation is also a more cost-effective treatment option for patients with
end-stage renal disease. Dialysis is an expensive procedure, costing the healthcare system
millions of dollars every year (21, 22). In Canada the cost for dialysis treatments is
approximately $60,000 per patient per year, while in comparison the cost of a one-time
kidney transplant is approximately $23,000 plus an additional $6000 for annual transplant
medications (10). If all 3000 individuals on the wait list for a kidney transplant received a
kidney, it would save the healthcare system an estimated $150 million dollars annually
(23).
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Rates of living kidney donation have been increasing worldwide to address the organ
shortage, with over 27,000 individuals choosing to donate every year (1). Living donation
is practiced under the framework that minimal medical risks faced by the donor are
outweighed by better recipient health and possible psychological benefits of altruism to
the donor (24). There is global consensus for a need to better understand the long-term
risks faced by living kidney donors, a historically neglected area (25). For this reason,
this topic has been the subject of active research. Better knowledge of the long-term
outcomes of individuals who become living kidney donors maintains public trust in the
transplantation system, informs the choices of potential donors and recipients, and guides
follow-up care to maintain optimal long-term health. Recent high-quality studies have
examined outcomes of mortality, cardiovascular events, end-stage renal disease, acute
kidney injury with receipt of dialysis, and fragility fractures after kidney donation (2628). Reassuringly, these studies did not find an increase in risk, adding to the evidence
base supporting the safety of the practice among carefully selected donors. However,
there are still other important outcomes which remain to be studied.
2.4 Kidney stones
Kidney stones or renal calculi are a common occurrence, with a prevalence of
approximately 5.2% in North America and an estimated lifetime risk of 10-15% (3, 29).
After the development of a kidney stone, the risk of a subsequent stone increases with a
recurrence rate of 75% over 20 years (2, 3). Kidney stones result from an abnormal
urinary composition, which cause the crystallization of stone-forming salts.
Approximately 80% of stones are formed from calcium-based salts, while the remainder
form from compounds like uric acid, cystine and struvite (30). Abnormalities in urinary
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composition can be caused by both metabolic and environmental factors (2).
Environmental factors include hot climate (certain regions within the US are referred to
as the ‘stone belt’ due to a higher prevalence of kidney stones because of climate),
strenuous exercise, and diets rich in animal protein and salt. Metabolic factors include
hypercalciuria (increased absorption of calcium in the intestine or decreased absorption in
the kidney) and hypocitraturia (excess dietary acid) (2).
Epidemiological studies have identified several risk factors associated with the formation
of kidney stones. Literature describes males having a 2-3 times higher risk of developing
kidney stones than females (29, 31, 32). The peak incidence of kidney stones occurs
during the age range of 40-50 years (29, 33-35).
2.5 Treating kidney stones
The majority of stones are small enough to pass through the urinary tract spontaneously
without any intervention. This typically occurs within four weeks after the onset of
symptoms (4). However, if the kidney stone does not resolve with expectant
management, a urologist may choose to surgically intervene using shockwave lithotripsy,
ureteroscopy or percutaneous nephrolithotomy (4). Surgical procedures are usually
required when stones are 3 mm or greater in size (3, 4). Approximately 10-20% of kidney
stones are treated surgically (32).
Extracorporeal shockwave lithotripsy is a procedure that involves targeting a shockwave
from an external source, propagating through the patient’s body to the kidney stone
causing it to break into smaller fragments. These fragments are then removed or allowed
to pass spontaneously (4, 36, 37).
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Ureteroscopy requires the use of an endoscope to visualize the urinary tract and
collecting system. Ureteroscopes enable the use of other instruments to allow for stone
fragmentation and removal (4, 37).
Percutaneous nephrolithotomy is a procedure during which the surgeon makes a small
incision in the patient’s back to remove the kidney stone using a hollow tube and a probe
(4). Sometimes a laser is used to fragment the kidney stone. The fragments are then
removed using basket extraction or a suction device (4, 37).
2.6 Kidney stones in living kidney donors
In a patient with a solitary kidney, the development of a kidney stone is potentially more
serious. If the kidney stone obstructs the ureter, this usually requires an emergency
surgical intervention to prevent acute renal failure (5). Literature has also demonstrated
that kidney stones can result in a decline in renal function (38, 39). In an individual with
one kidney, the consequences of this could potentially be more severe as they do not have
a second kidney to compensate for the reduced renal function.
On review of the literature, no risk estimates of kidney stones in living kidney donors
were found. Instead the majority of the literature described donor-gifted lithiasis (5, 4045). This occurs when a stone is found in the donor kidney (either living or deceased) at
the time of transplantation surgery. Normally the identified stone is removed immediately
before transplantation into the recipient, or it is left as is if deemed small enough to not
cause any complications to the recipient. However, all these studies only describe kidney
stones which occurred prior to transplant, when the donor still had two kidneys.
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While the risk of kidney stones in living kidney donors has not been reported in
literature, there have been case reports and discussions of treatment for kidney stones in
individuals with a solitary kidney for any reason (46-51). One study comparing solitary
and bilateral kidney patients being treated with percutaneous nephrolithotomy described
individuals with a solitary kidney as having undergone significantly more procedures to
remove kidney stones prior to the study (46). However, all of these studies focused on the
method of treatment and did not provide estimates of the risk of kidney stones in
individuals with a solitary kidney for any reason.
2.7 Studying long-term outcomes of living kidney donors
There are four major challenges to obtaining reliable estimates of the long-term risks
associated with becoming a living kidney donor:
1) Many donors do not reside close to a transplant centre, and their only purpose of
visiting is to donate their kidney to the recipient. Beyond the first year after
nephrectomy the majority of donors do not follow-up with the transplant centre.
This makes it challenging to follow all donors for a given transplant centre over
many years (where loss to follow-up can result in both selection biases and
information biases).
2) People experience health events as they age, and so when we observe such events
in donors during follow-up it is questioned whether such events occurred due to
aging and were unrelated to the donation process, or whether they are a biological
consequence of nephrectomy. The only reliable way to solve this issue is to also
study a non-donor ‘control’ group, where the rate of events observed in follow-up
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can be compared between donors and non-donors to establish any true risk
attributable to donation.
3) Choosing the best type of non-donors to compare to the donors is central to any
study of relative risks associated with donor nephrectomy (52). Donors go
through a detailed selection process and are inherently healthier than the general
population (53). Thus the ideal non-donor controls are those individuals who have
a similar health state to donors at the time of nephrectomy.
4) It may take years for biological changes from donation to manifest. To achieve
such a long follow-up in a prospective study requires years of waiting and is an
expensive proposition.
The need for solutions to generate reliable information on long-term living donor
outcomes was recently outlined in a State of the Art Conference with international
opinion leaders (54). To address this need we are fortunate to have developed a unique
cohort in Ontario, Canada. This cohort addresses the four challenges described above and
its strengths are internationally recognized.
2.9 Health administrative data in Ontario
Ontario currently has approximately 13 million residents who have universal access to
hospital and physician care (55). The province’s administrative healthcare databases
provide a rich data source unique to Canada, which is representative of the entire
province. Using these databases allows us to address weaknesses faced by prospective
studies by minimizing selection and information biases, allowing for large sample sizes
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and long periods of follow-up, as well as minimizing any loss-to-follow up (only due to
emigration out of the province, <0.5% per year).
In order to study the outcomes of living kidney donors, we manually reviewed the
medical charts of over 2000 living kidney donors, and then linked this information to
provincial healthcare databases housed at the Institute of Clinical Evaluative Sciences
(ICES). We isolated the healthiest segment of the general population, providing us with a
suitable non-donor comparison group.
We have successfully leveraged this cohort in the past to provide much needed
information on the risk of cardiovascular events, acute kidney injury with receipt of
dialysis and fragility fractures in living kidney donors (published in the British Medical
Journal (BMJ), Nephrology Dialysis Transplantation (NDT) and American Journal of
Kidney Diseases (AJKD) respectively) (26-28).
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3.1 Rationale
We performed detailed searches of Pubmed, EMBASE and Google Scholar, and
determined that there are no existing studies that evaluate the long-term risk of kidney
stones in living kidney donors. When we expanded our search to include individuals with
a solitary kidney for any reason, we still failed to find any description of the risk of these
long-term outcomes (56).
We did find some information on the treatment of kidney stones in patients with a single
kidney. Individuals with a solitary kidney treated with percutaneous nephrolithotomy had
less favourable outcomes compared to those with two kidneys (46). Patients with a
solitary kidney also underwent more procedures to remove kidney stones compared to
those with two kidneys (46).
There is no reason to suspect that living kidney donors would have a higher risk of
kidney stones than members of the general population. Yet, a kidney stone in an
individual with a solitary kidney can potentially obstruct the ureter, leading to acute renal
failure and may result in urgent hospital attention and even surgical intervention. This is
also a concern because kidney stones can result in a decline in renal function, and this
risk may be even higher in donors compared to non-donors (38, 39).
Given the current state of the literature, the study we conducted is novel and meets an
information need.
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3.2 Research Question & Hypothesis
We conducted this matched retrospective cohort study to determine if living kidney
donors compared to healthy non-donors have a higher risk of: 1) kidney stones with
surgical intervention, and 2) hospital encounters for kidney stones.
Hypothesis: We expected that living kidney donors may be at greater relative risk for
kidney stones with a surgical intervention compared to a group of healthy non-donors
(where kidney stones which develop in follow-up will be less likely to result in an
intervention). However, the absolute increase in risk will be low when compared to the
control group of non-donors.
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Chapter 4: Methods
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4.1 Study design
We conducted a matched retrospective cohort study using Ontario’s administrative
healthcare databases held at the Institute for Clinical Evaluative Sciences (ICES).
4.2 Data sources and data collection: Ontario healthcare databases
The following databases were used to ascertain our variables of interest:
The Trillium Gift of Life Network (TGLN) is Ontario’s central organ and tissue donation
agency with information on kidney donors and recipients in Ontario. We used the TGLN
database to identify living kidney donors, the main exposure group in this study. During
the years 2008 to 2010 we manually reviewed each of the medical charts of over 2000
living kidney donations which occurred between 1992 and 2009 at the five major
transplant centres in Ontario. The five major transplant centres include London, Ottawa,
Hamilton and the two centres in Toronto. I personally was responsible for reviewing all
charts from the London, Ontario centre. The living donor information in the TGLN
database is now complete, updated and accurate up to 2009.
The Canadian Institute for Health Information Discharge Abstract Database, Same Day
Surgery, and National Ambulatory Care Reporting System (CIHI-DAD, SDS, NACRS)
databases collect demographic, diagnostic, and procedural variables for inpatient,
emergency department and outpatient visits. Diagnostic and inpatient procedural coding
uses the 9th version of the Canadian Modified International Classification of Disease
system (ICD-9 CA) prior to 2002 and the 10th version (ICD-10 CA) thereafter. We used
the CIHI datasets to identify the occurrence of kidney stones with surgical intervention.
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We also used the datasets to identify any comorbid conditions which acted as exclusion
criteria for the non-donor controls (see codes in Table 1).
The Ontario Health Insurance Plan (OHIP) captures information on inpatient, outpatient,
and laboratory services based on billing claims from Ontario physicians. In chart
abstraction studies, agreement between abstracted OHIP codes and the actual codes the
physicians recorded on the chart for the “most responsible” diagnosis was over 90%
while agreement for procedural codes was over 88% (57). We used OHIP diagnostic
codes to identify baseline conditions and both procedural and diagnostic codes to define
our outcomes.
The Registered Persons Database (RPDB) captures demographic information on Ontario
residents including their sex, date of birth, postal code and vital status. We used the
RPDB to ascertain baseline demographics, exclusion criteria and potential confounders.
4.3 Cohort selection
Kidney donors undergo a complete medical evaluation to ensure they are in excellent
health prior to donation. In this study the date of nephrectomy was used as the date of
cohort entry, and is also referred to as their index date. The accrual period was from July
1st, 1992 to March 31st, 2012. To select a similar group of healthy non-donor controls,
we first randomly assigned an index date to all adults in the population of Ontario,
following the distribution of index dates in living kidney donors. For the control
population we excluded all individuals who have evidence of a medical condition prior to
their index date which would preclude them from becoming a living kidney donor (such
as diabetes, hypertension or kidney disease). From the remaining controls we then
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utilized a technique of matching, such that each donor was matched to ten non-donor
controls based on index date (± 6 months), age (± 2 years), sex, neighbourhood income
quintile, and residential status (rural, urban). This process of: i) restricting the non-donor
control sample to the healthiest segment of the population, and ii) matching donors and
non-donors on key characteristics, represents our primary strategies to minimize
confounding. Typically studies have demonstrated a limited increase in precision when
the ratio of controls to cases is increased beyond four (58-60). However, given that our
study was conducted using administrative data from the entire province of Ontario, it was
feasible for us to obtain additional matched controls resulting in a slight increase in
precision.
We followed our donors and non-donor controls for outcomes of interest until March
31st, 2012 (last date of follow-up). We have successfully used a similar technique to
report the risk of cardiovascular events, acute kidney injury with dialysis and fracture
outcomes in donors and non-donor controls (26-28).
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Figure 1: Cohort selection flowchart for living kidney donors

All LKDs identified in TGLN
between July 1992 and March 2009,
from major transplant center
(n=2083)
Listed as LKD more than once (n=4)
Donor IKN=Recipient IKN (n=9)
Dialysis code from July 1991 to 4
months after index date (n=13)
Date of last contact <4 months after
index date (n=15)
Age <18 years at index date (n=1)
Pregnant at time of donation (n=9)
Evidence of kidney stones with surgical
intervention/ hospital encounter for
kidney stones (n=13)

Included LKDs (n=2019)

LKD: Living Kidney Donor
IKN: ICES Key Number
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Figure 2: Cohort selection flowchart for healthy non-donors

Include:

Exclude:

All residents of Ontario
registered in RPDB
(n=71,792,616)

Potential controls
(n=13,461,161) given
randomly assigned
index date

Potential controls
(n=13,461,161)

RPDB: Registered Persons Database
IND: Index date
DOLC: Date of Last Contact

Date of death before July 12, 1992 (n=157,868)
Age < 18 years on March 31, 2012 (n=3,743,913)
Age > 75 years on July 12, 1992 (n=429,674)

Date of death before IND (n=398,776)
Age <18 on >75 on IND (n= 2,015,577)
Death < 4 months after IND (n= 40,346)
DOLC <4 months after IND (n= 1,041,351)
Zero or >4 physician visits in 2 years prior to IND
(n=8,143,158)
Pregnant (<2 months prior and 6 months after) (n=8,610)
Prior to IND:
Diabetes (n=23,564)
Hypertension (n=81,947)
Cancer (n=45,752)
Cardiovascular disease or surgery (n=30,478)
Pulmonary disease (n=107,369)
Liver disease (n=14,416)
Systemic lupus erythematosus (n=45)
Rheumatoid arthritis (n=278)
HIV (n=49)
Listed as kidney donor or recipient (n=444)
Genitourinary disease (n=59,866)
Nephrectomy (n=37)
Renal biopsy (n=30)
Dialysis (n=628)
Nephrologist consultation (n=5,497)
Gestational diabetes (n=374)
Pre-eclampsia (n=3,710)

Prior to and 7 days after IND:
Kidney stones with surgical intervention (n=1,856)
Other hospital encounters for kidney stones (n=2,564)
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4.4 Study Population
Donors were those individuals who donated a kidney at one of the five major adult
transplant centers in Ontario.
Our exclusion criteria for donors included the following:
1) Evidence of kidney stones prior to index date (to ensure we capture only de novo
events in follow-up: also the number of donors with a prior history of kidney
stones is uncommon in our setting, and we cannot meaningfully look at this small
group of patients).
As mentioned above, non-donor controls must be in good health to ensure they are
comparable to living kidney donors who undergo rigorous medical assessment in order to
qualify for donation. To create an appropriate non-donor control group with similar
health status to our donor group, we excluded all individuals from the general population
with evidence of a contraindication to donation including the following:
1) Any of the following conditions: Diabetes, hypertension, cancer, cardiovascular
disease (including any heart disease, stroke or peripheral vascular disease),
pulmonary disease, liver disease, systemic lupus erythematosus, rheumatoid
arthritis, HIV, gestational diabetes, pre-eclampsia, kidney stones or any
genitourinary disease renal disease (including a history of nephrectomy, kidney
transplant, kidney biopsy, or dialysis) (53).
2) Pregnant at the time of index date (ineligible to donate a kidney at that time).
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3) Evidence of kidney stones with surgical intervention prior to the index date (as
this same exclusion criteria is being used in our donor cohort).
4.5 Outcome: Kidney stones with surgical intervention
Our primary outcome was the evidence of kidney stones with surgical intervention
following the index date until March 31st, 2012 (see Appendix 2 for codes). These codes
have not been formally validated but are expected to have high sensitivity and specificity
similar to other fee for service codes (61). The codes were also chosen based on clinical
expertise and an understanding of urology billing practices.
All participants were followed up from index date until: i) death, ii) emigration from the
province, or iii) the end of study period (March 31, 2012). Of the individuals who
reached the end of the study (March 31, 2012), those whose most recent healthcare
encounter was more than three years before the end of study (March 31, 2012) were
classified as having emigrated from the province. These individuals were censored at one
year following their last healthcare encounter.
Outcomes include recurrent events (participants can have more than one occurrence of a
kidney stone with surgical intervention during follow-up, but such interventions must be
separated by at least 90 days to ensure it is an intervention for a new stone or
reoccurrence of a stone).
4.6 Data Analysis
Descriptive Statistics and Baseline Characteristics: We described the continuous baseline
characteristics as means with standard deviations for normally distributed data or as
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medians with interquartile ranges for skewed data. We presented categorical variables as
proportions. We assessed the differences between donors and non-donors using
standardized differences (62). Standardized differences are less sensitive to sample size
than traditional hypothesis tests. They provide a measure of the difference between
groups divided by the pooled standard deviation, where a value greater than 10% is
interpreted as a meaningful difference between the groups (62). Our data sources and
variables of interest were complete. In previous studies missing data has been < 1% (2628).
Primary analyses: We used a negative binomial model stratified on matched sets to
estimate the rate ratio and 95% confidence interval. This model also accounts for the
possibility of a person having more than one stone event in follow-up (defined by events
separated by at least 90 days). We repeated the primary analysis in three pre-specified
subgroups defined by age (<40 vs ≥40 at index date), sex and index date (1992 to 2001
[median follow-up 13.3 years, interquartile range (IQR) 11.4 to 15.8] vs. 2002 to 2009
[median follow-up 5.9 years, IQR 4.3 to 7.8]).
Additional analyses: We examined whether rate ratios differed among subgroups using a
series of pair-wise standard z-tests. We repeated the primary analysis using Kaplan-Meier
estimates stratified on matched sets to examine the first stone event in follow-up for both
the primary and secondary outcomes. We examined the characteristics associated with
stone events separately in donors and non-donors using negative binomial regression
models. All analyses were performed at ICES with SAS software version 9.2 (SAS
Institute, Cary, NC).
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Table 1 provides sample size calculations based on α = 5%, 1 – β = 80%, an incidence of
2.5% in non-donors, a 1:10 ratio of kidney donors to non-donors, and a continuity
correction for the difference in proportions. Based on these calculations, we only required
1515 donors and 15150 non-donors to detect an odds ratio of 1.5 over a median follow-up
of 11 years, should an association exist. These are numbers well below our attained
sample.
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Table 1. Sample size calculations
Presented are the number of individuals required in each group to detect a defined
difference in the rate ratio should it in truth exist.

Rate Ratio to be
detected
1.50

1.75

1515

696

Living kidney donors

15150

6960

Non-donor controls

Assumptions: The proportion of non-donor controls who will develop a kidney stone over
a median follow-up of 6 years is 2.5%. α = 0.05, 1-β = 0.8, a ratio of kidney donors to
non-donor controls of 1:10. To simplify the calculations these analyses disregard the
matching used to generate the sets and only consider the development of the first kidney
stone in follow up. A continuity correction was used for the difference in proportions.
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Chapter 5: Results

29

5.1 Baseline characteristics
Table 2 shows the baseline characteristics of the selected 2,019 donors and 20,190
matched non-donors. Donors and non-donors had similar baseline characteristics. The
median age at index date was 43 years (interquartile range 34 to 50) and median age at
last follow-up was 52 years (interquartile range 44 to 60). Approximately 60% of the
donor and non-donor cohorts were female, and 13% had a rural residency status.
Approximately 62% of donors are first degree relatives of the recipient, with roughly
35% donating to a sibling, 14% donating to a parent, and 13% donating to their child.
The remaining living kidney donors donated to their spouse (20%), another relative (6%)
or to an unrelated individual (12%). Donors had a median of 11 physician visits in the
year prior to the index data, compared to a median of 1 physician visit in non-donors.
This difference is expected, given the thorough medical work-up which is a necessary
part of the donor evaluation process.
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Table 2.
Baseline characteristics of donors and healthy non-donors at the time of cohort entry.
Donors
n = 2,019

Non-donors
n = 20,190

43 (34 – 50)

43 (34 – 50)

1,213 (60%)
270 (13%)

12,130 (60%)
2700 (13%)

Income quintile
Lowest
Middle
Highest

308 (15%)
423 (21%)
463 (23%)

3,080 (15%)
4,230 (21%)
4,630 (23%)

Physician visits in prior year*

11 (8 – 15)

1 (0 – 2)

Year of cohort entry
1992 – 1997
1998 – 2003
2004 – 2009

391 (19%)
729 (36%)
899 (45%)

3915 (19%)
7285 (36%)
8990 (45%)

Age, years
Women
Rural town

Data presented as median (interquartile range) or as number (percent). The time of cohort entry is
also referred to as the index date. This was the date of nephrectomy in donors and was randomly
assigned to non-donors to establish the time follow-up began.
*Indicates a standardized difference between donors and non-donors greater than 10%. As
expected, donors had more physician visits in the year prior to index date compared to non-donors,
as such visits are a necessary part of the donor evaluation process.
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The median length of follow-up was 8.4 years (8.8 years in donors, 8.4 years in nondonors, maximum 19.7 years). A total of 856 donors and 8,128 non-donors had over 10
years of follow-up. The median age at the time of last follow-up for the entire cohort was
52 years (interquartile range 44 to 60). Of the 22,209 individuals (2,019 donors, 20,190
non-donors), 20,084 (90.4%) reached the end-of-study follow-up (March 31, 2012),
1,499 (6.7%) were censored at emigration from the province, 480 (2.2%) were censored
at the time of death and the remainder received at least one intervention for kidney
stones. Total person years of follow-up were 204,199 (19,118 donors, 185,081 nondonors).
5. 2 Outcomes
The main outcomes are presented in Table 3 and Figures 3a and 3b. There were 195
events of kidney stones with surgical intervention (16 in donors, 179 in non-donors). The
rate of this event was no different in donors compared to non-donors (8.3 vs 9.7 events
per 10,000 person-years; rate ratio, 0.85; 95% confidence interval (CI) 0.47-1.53). There
were a total of 323 events of hospital encounters for kidney stones (23 in donors, 300 in
non-donors) recorded in our data sources. The rate of this event was no different in
donors compared to non-donors (12.1 vs 16.1 events per 10,000 person-years; rate ratio
0.75; 95% CI 0.45-1.24). The results for both outcomes were the same when we assessed
the time to first event (kidney stone with surgical intervention: hazard ratio 1.04, 95% CI
0.60 – 1.80; hospital encounter for kidney stone: hazard ratio 0.81, 95% CI 0.51 – 1.30;
see figures 3a and 3b for Kaplan-Meier curves).
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Table 3. Primary and secondary outcome events among donors and non-donors.

Median follow-up, years (IQR)
Range follow-up, years (min, max)
Total follow-up, person-years
No. (%) of events:
0
1
2
≥3
No. of events per 10,000 person years
Model based rate ratio †

Kidney stones with surgical intervention
Donors
Non-donors
(n=2,019)
(n=20,190)
8.8 (5.6 – 12.9)
8.4 (5.3 – 12.6)
0.55, 19.7
0.34, 19.7
19118
185080
2,005 (99%)
12 (0.6%)
≤5*
≤5*
8.3
0.85 (0.47 – 1.53)

20,058 (99%)
105 (0.5%)
12 (0.1%)
15 (0.1%)
9.7
1.00 (reference)

Data presented as number (percentage) or value (95% confidence interval) unless otherwise specified.
IQR (interquartile range)
*cell counts less than or equal to 5 have been suppressed for reasons of privacy.
†p-values=0.58 and 0.27, respectively.

Hospital encounter for kidney stones
Donors
Non-donors
(n=2,019)
(n=20,190)
8.8 (5.6 – 12.9)
8.4 (5.3 – 12.6)
0.55, 19.7
0.34, 19.7
19118
185080
2,000 (99%)
15 (0.7%)
≤5*
≤5*
12.1
0.75 (0.45 –
1.24)

19,965 (99%)
182 (0.9%)
23 (0.1%)
20 (0.1%)
16.1
1.00 (reference)
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Figure 3a. Kaplan-Meier curve of time to first kidney stone with surgical intervention.
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Figure 3b. Kaplan-Meier curve of time to first hospital encounter for a kidney stone.
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Subgroup analyses are shown in Figures 4a and 4b. Older age at study enrolment, sex,
and earlier date of enrolment (longer follow-up) did not influence the association between
living kidney donation and risk of kidney stones with surgical intervention (p value for
interaction ranged from 0.40 – 0.80). Subgroup results were similar for the secondary
outcome of hospital encounters of kidney stones, with one exception: the rate ratio
between living donation and outcome was lower in men compared to women. In the
subgroup of men donors had a lower (not higher) risk of the outcome than non-donors.
When donors and non-donors were examined separately, the 95% confidence
intervals of risk factor rate ratios were more precise in non-donors (expected as there
were 10 times as many non-donors as donors). In donors, no significant associations
were observed between various risk factors (age, sex, rural residence, income quintile,
and year of index date) and the primary or secondary outcomes (Table 4). In non-donors,
older age and male sex were associated with an increased risk of kidney stones with
surgical intervention and hospital encounters for kidney stones.
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Figure 4a. Influence of age, sex, & index date (length of follow-up) on primary outcome of kidney stones with surgical intervention.

*Individuals with index date of 1992-2001 had median follow up of 13.3 years, interquartile range (IQR) 11.7 to 16.0; individuals with index date of 2002-2009 had median
follow-up of 5.9 years, IQR 4.3 to 7.8.

37

Figure 4b. Influence of age, sex, & index date (length of follow-up) on secondary outcome of hospital encounters for kidney stones.

*Individuals with index date of 1992-2001 had median follow up of 13.3 years, interquartile range (IQR) 11.7 to 16.0; individuals with index date of 2002-2009 had median
follow-up of 5.9 years, IQR 4.3 to 7.8.
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Table 4. Risk factors for kidney stones in donor and non-donors when each group was analyzed separately.

Donors

Non-donors

Kidney stones with surgical intervention
Older age (per 5 years)
Women (vs. men)
Rural residence (vs. urban residence)
Higher income quintile
More recent year of index date

1.15 (0.90 – 1.50)
0.92 (0.30 – 2.85)
2.49 (0.29 – 21.65)
0.87 (0.59 – 1.29)
0.97 (0.85 – 1.11)

1.12 (1.02 – 1.23)
0.49 (0.34 – 0.73)
1.04 (0.59 – 1.84)
0.95 (0.82 – 1.10)
0.99 (0.94 – 1.04)

Hospital encounters for kidney stones
Older age (per 5 years)
Women (vs. men)
Rural residence (vs. urban residence)
Higher income quintile
More recent year of index date

1.02 (0.82 – 1.26)
1.60 (0.56 – 4.58)
1.74 (0.33 – 9.06)
1.00 (0.70 – 1.43)
1.01 (0.91 – 1.13)

1.08 (1.01 – 1.15)
0.46 (0.34 – 0.61)
1.08 (0.70 – 1.67)
0.92 (0.82 – 1.02)
0.98 (0.95 – 1.02)

Separate negative binomial models were created for donors and non-donors. Presented are the rate ratios and 95%
confidence intervals.
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Chapter 6: Discussion
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6.1 Overview of findings
We hypothesized that a donor with one kidney might receive surgical intervention for a
stone more frequently than a non-donor with two kidneys presenting with a stone.
Similarly, we expected that donors with stones might be more likely to present to
hospital. However, our findings do not support these hypotheses. In this study, we
determined that the rates of 1) kidney stones with surgical intervention, and 2) hospital
encounters for kidney stones, were not significantly different between donors and nondonors. The majority of living kidney donors (99.3%) did not experience a kidney stone
intervention or hospital encounter over a median follow-up of 8.8 years (maximum
follow-up 19.7 years). There was also no evidence that donation increased the risk of
either kidney stone event when examined in subgroups defined by age, sex, or index date
(length of follow-up). The Kaplan-Meier curves after 10 years of follow-up did not
suggest any higher risk of stone events in donors compared to non-donors.
When non-donors were examined using a separate negative binomial model, both older
age, and male sex were associated with an increased risk of kidney stones with surgical
intervention, and hospitalization for kidney stones. This finding is consistent with
previous literature, which has established age and male sex as known risk factors for
kidney stones (29, 31). We did not find this to be the case within the donor cohort when
analyzed separately, though we did expect these risk factors to behave similarly.
However, this can be explained by the limited number of kidney stone events within the
donor cohort, preventing us from reliably assessing these risk factors in the separate
analysis.
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Overall, these findings are reassuring towards the practice of living kidney donation. It
demonstrates the effectiveness of the thorough screening that donors undergo prior to
donation.
6. 2 Strengths
Our study has a number of strengths. To our knowledge this is the first study to report on
a donor’s long-term risk of kidney stones after living kidney donation. The universal
healthcare benefits available to all Ontario residents allowed us to efficiently study all
living donation activity in the largest province of Canada, minimizing both information
and selection biases. We ensured the accuracy of donor data captured in the Trillium Gift
of Life database through the manual review of over 2000 pre-donation medical charts at
the five major transplant centres in Ontario. We addressed potential confounders by
matching donors and non-donors on risk factors associated with kidney stone events such
as older age and male sex (29, 31). Loss to follow-up, which is a concern in most longterm donor studies, was minimal in our study with less than 7% censored in follow-up at
the time of emigration from the province.
6.3 Limitations
Our study does have some limitations. The retrospective nature of the study prevented
us from controlling the assessment of the exposure and outcome, meaning we relied on
administrative data collected for non-research purposes. The use of administrative data
limited us with regards to: the types of data and variables that were available to us, how
we ascertained our outcomes, and our inclusion and exclusion criteria for the selection of
the donor and healthy non-donor cohorts.
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Our administrative data sources also prevented us from addressing some potential
confounders. We had no baseline or follow-up information in our data sources on dietary
risk factors for stones such as water intake, salt consumption and calcium
supplementation (2, 63). We did not take other known risk factors for kidney stones
including race and Body Mass Index (BMI) into account because they could not be
accurately ascertained using our data sources. However, given that 75% of the Ontario
population is Caucasian, we expect our results to generalize well to Caucasian donors but
not to other races. Previous literature has observed a higher prevalence of kidney stones
in American Caucasians when compared to African Americans and Hispanics in the
United States (64). Additionally, given Ontario’s relatively uniform climate, the observed
rates would not be comparable to regions within the kidney stone belt which are typically
higher because of elevated temperatures.
Unlike the donors, most non-donors did not have routine imaging to rule out the presence
of baseline asymptomatic kidney stones. Residual confounding, which is inherent to any
observational study, may affect the association between living kidney donation and the
outcome of interest seen in our study.
We relied on clinical expertise and knowledge of billing practices to define our outcomes,
as the codes were either not validated or partially validated. There are no reliable codes to
detect kidney stones that do not present to hospital attention. Also, codes to detect kidney
stones presenting to hospital are insensitive and underestimate the true incidence of the
event.(65) However, this is not the case for kidney stones requiring surgical intervention
and we do not anticipate coding inaccuracies in stones presenting to hospital were
differential between donors and non-donors (i.e. estimates of relative risk are valid).
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6.4 Future Directions
While these findings are reassuring for the practice of living kidney donation, it is
possible that the risk may take longer to manifest. In order to fully understand the longterm risk of kidney stones with surgical intervention in living kidney donors, we will
continue to follow our cohort in order to obtain several additional decades of follow-up.
While living kidney donation is the preferred treatment option for individuals living with
renal failure, the supply still does not meet the growing demand for organs. In order to
address this discrepancy, efforts are being made to increase the number of living
donations through the acceptance of expanded criteria donors. Expanded criteria donors
are donors who may not meet the strict donation criteria, but are deemed sufficiently
healthy enough to donate. Having a history of kidney stones was once a contraindication
to becoming a living kidney donor. However, this criterion has become more relaxed in
recent years. Our study does not provide evidence regarding the safety of this practice, as
we assessed the de novo formation of kidney stones. Additionally these results should not
be used to justify expansion of donor eligibility to those with risk factors for stones, such
as obesity or a prior history of stones (3, 31, 66). Rather, this is only the first step in
understanding the risk to expanded criteria donors. We have simply established that the
baseline risk of kidney stone events in donors selected using the strict standard criteria is
no different than in healthy non-donors. Further studies, following donors with a history
of kidney stones, are needed to establish whether it is safe for such individuals to become
donors.
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In addition, future studies can assess the risk of any kidney stone event, not simply those
requiring hospital encounters or surgical intervention. This would first require the
validation of the ICD-9 and ICD-10 codes for diagnosis of kidney stones in order to
accurately assess the risk of these events using administrative healthcare databases.
However, a prospective cohort study would be the optimal method to ascertain a living
kidney donor’s risk of developing kidney stones post-donation. This would allow
additional important confounders like diet, race, BMI, and family history of kidney
stones to be addressed (32, 66, 67). Imaging could be performed on participants to
identify the formation of asymptomatic kidney stones as well.
6.5 Conclusion
Through this study we have determined that the risks of 1) kidney stones with surgical
intervention, and 2) hospital encounters for kidney stones are no different between living
kidney donors and matched healthy non-donors. As we continue to follow this study
cohort, these interim findings are reassuring to the safety of the practice of living kidney
donation.
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Appendix A: Checklist of recommendations for reporting of observational studies
using the STROBE (STrengthening the Reporting of OBservational studies in
Epidemiology) guidelines.
Item
No

Title and abstract

Reported
Recommendation
(a) Indicate the study’s design with a commonly
used term in the title or the abstract

abstract

(b) Provide in the abstract an informative and
balanced summary of what was done and what was
found

abstract

1

Introduction
Background/rationale

2

Explain the scientific background and rationale for
the investigation being reported

introduction

Objectives

3

State specific objectives, including any prespecified
hypotheses

introduction

Study design

4

Present key elements of study design early in the
paper

methods

Setting

5

Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure, followup, and data collection

methods

(a) Give the eligibility criteria, and the sources and
methods of selection of participants. Describe
methods of follow-up

methods

(b)For matched studies, give matching criteria and
number of exposed and unexposed

methods

7

Clearly define all outcomes, exposures, predictors,
potential confounders, and effect modifiers. Give
diagnostic criteria, if applicable

methods

8

For each variable of interest, give sources of data
and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one group

methods

Bias

9

Describe any efforts to address potential sources of
bias

methods

Study size

10

Explain how the study size was arrived at

methods

Methods

Participants

Variables

Data sources/
measurement

6
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Quantitative variables

11

Statistical methods
12

Explain how quantitative variables were handled in
the analyses. If applicable, describe which
groupings were chosen and why

methods

(a) Describe all statistical methods, including those
used to control for confounding

methods

(b) Describe any methods used to examine
subgroups and interactions

methods

(c) Explain how missing data were addressed

not applicable

(d) If applicable, explain how loss to follow-up was
addressed

not applicable

(e) Describe any sensitivity analyses

not applicable

(Continued on next page)
Results

Participants

Descriptive data

Outcome data

Main results

(a) Report numbers of individuals at each stage of
study—e.g. numbers potentially eligible, examined
for eligibility, confirmed eligible, included in the
study, completing follow-up, and analysed

Methods, results

(b) Give reasons for non-participation at each stage

methods

(c) Consider use of a flow diagram

methods

13

14

15

16

(a) Give characteristics of study participants (e.g.
demographic, clinical, social) and information on
exposures and potential confounders

table 1

(b) Indicate number of participants with missing
data for each variable of interest

not applicable

(c) Summarise follow-up time (e.g. average and
total amount)

table 2

Report numbers of outcome events or summary
measures over time

results, table 2

(a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision
(e.g. 95% confidence interval). Make clear which
confounders were adjusted for and why they were
included

results, table 2

(b) Report category boundaries when continuous
variables were categorized

table 1
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(c) If relevant, consider translating estimates of
relative risk into absolute risk for a meaningful time
period

not applicable

17

Report other analyses done—e.g. analyses of
subgroups and interactions, and sensitivity analyses

Results, table 3

Key results

18

Summarise key results with reference to study
objectives

discussion

Limitations

19

Discuss limitations of the study, taking into account
sources of potential bias or imprecision. Discuss
both direction and magnitude of any potential bias

discussion

Interpretation

20

Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other
relevant evidence

discussion

Generalisability

21

Discuss the generalisability (external validity) of
the study results

discussion

22

Give the source of funding and the role of the
funders for the present study and, if applicable, for
the original study on which the present article is
based

Other analyses
Discussion

Other information

Funding

acknowledgements
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Appendix B: Kidney stone codes
KIDNEY STONE WITH SURGICAL INTERVENTION
OHIP fee codes
CCI
Z630 (Extracorporeal shock wave
Stone Destruction
lithotripsy)
1pe59
(renal pelvic,
E773 (Stent with stone)
ureteropelvic junction)
Z629 (perinephrium percutaneous
nephrostomy)
Z623 (Kidney, perinephrium insertion of
stent)
J046 (Diagnostic radiology, percutaneous
nephrostomy)
Z624 (Kidney perinephrium dilation of
tract)

1pg59
(ureter, ureterovesical
junction)
1pm59
(urinary stoma, cystomy,
nephrostomy,
ureterostomy)
1pv59
(surgically created
urinary tract)

Z627 (Kidney-removal of renal calculi)
E759 (Disintegrated by US. add to
removal renal calculi)
E772 (Percut rem. staghorn calc. renal
pelvis, add)
Z628 (Ureteroscopy/cystoscopy above
intramural ureter)
E760 (Ureter-removal of stone add cysto
& ureteroscopy)
E761 (Ureter-if disintegrat.by US add to
cysto & ureterosc.)
Z627 (Kidney-removal of renal calculi)
S430 (Kidney-litholapaxy-staghorn
calculus,incl. X-ray)
S405 (Nephrolithotomy)
S408 (Pyelolithotomy)

Stone Extraction
1pe57
(renal pelvic,
ureteropelvic junction)
1pg57
(ureter, ureterovesical
junction)
1pm57
(urinary stoma, cystomy,
nephrostomy,
ureterostomy)
1pv57
(surgically created
urinary tract)

CCP
67.03
(percutaneous
nephrostomy
without
fragmentation)
67.04
(percutaneous
nephrostomy
with
fragmentation)
68.95
(ureteroscopy)
71.96
(ultrasonic stone
fragmentation)
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S445 (ureterotomy removal of calculus
upper 2/3)
S446 (ureterotomy removal of calculus
lower 1/3)

NON-SURGICAL HOSPITAL ENCOUNTERS FOR KIDNEY STONES
ICD-9: 592, 592.0, 592.1, 592.9
ICD-10: N20

CCI: Canadian Classification of Health Interventions; CCP: Canadian Classification of Diagnostic, Therapeutic, and
Surgical Procedures
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Appendix C: Data Creation Plan

Risk of kidney stones with surgical intervention in living kidney donors
Study number

2013 0906 010 000

Research
program
Contacts

Kidney, Dialysis, Transplantation (KDT)

Updates by

Sonia Thomas
Anjie Huang
Amit Garg
Ngan Lam
Danielle Nash
Blayne Welk
Ramesh Prasad
Krista Lentine
Sonia Thomas

PIA approved?

Yes

DCP update
history

Version 1: October 29, 2012 (ST)
Version 2: November 13, 2012 (ST, after meeting with AG)
Version 3: November 16, 2012 (ST)
Version 4: November 19, 2012 (after call with AH, AG)
Version 5: November 28, 2012 (ST)
Version 6: December 17, 2012 (ST)

Research
question

To examine the long-term risk of kidney stones with intervention following living
kidney donation. The study will include all living kidney donors in the province of
Ontario who donated a kidney between July 1, 1992 and March 31, 2009. We will
compare the risk of kidney stones with intervention in LKD to healthy non-donor
controls.
Retrospective cohort study

Study design
List of datasets
used

1. Trillium Gift of Life Network (TGLN) [July 1992 – March 2009]
TGLN data
dictionary.doc

2. Ontario Diabetes Database (ODD) [July 1991 – March 2009]
3. Ontario Hypertension Database (OHD) [July 1991 – March 2009]
4. CIHI-DAD and CIHI-SDS [July 1991 – March 2012]
Source
All
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Institution types
All
5. NACRS [July 2000 – March 2012]
Source
ED
Include planned visits
Yes
6. Ontario Health Insurance Plan (OHIP) [July 1991 – March 2012]
Code Types
Feecodes
[see Appendices A, B, C, D, E embedded in exclusion criteria section for
codes]
7. Registered Persons Database (RPDB) [July 1991 – March 2012]

Defining the cohort
Index date
Inclusion
criteria

Date of kidney donation in TGLN (LIVING_DONORS_ENC.TX_DATE)
Retrospective cohort study comparing 2 groups:
Exposed: Individuals who have undergone living kidney donation and meet the
following requirements:
- Donated between July 1, 1992 and March 31, 2009 with a valid IKN
(LIVING_DONORS_ENC.valikn = ‘V’)
- Donation at a study eligible transplant center
(LIVING_DONORS_ENC.TX_HOSP_OTTAWA HOSPITAL GENERAL
CAMPUS; OTTAWA HOSPITAL CIVIC CAMPUS; ST JOSEPH'S
HEALTHCARE SYSTEM – HAMILTON, ST MICHAEL'S HOSPITAL –
[Toronto], TORONTO GENERAL HOSPITAL, UNIVERSITY HOSPITAL [London] ). In other words the hospitals excluded from the analysis are:
KINGSTON GENERAL HOSPITAL, THE HOSPITAL FOR SICK
CHILDREN)
Non-exposed: Individuals from the general population matched to the exposed
group (Medically eligible to donate a kidney, see “Exclusion Criteria”)

Cohort size

Anticipate approximately 2000 living kidney donors and 20,000 matched nondonor controls (1:10 match ratio)

Exclusion criteria
Exclusion
criteria for
DONORS
(in order)
(See Table 1)

Data cleaning steps
Exclude if:
1) Missing DOB in RPDB (expect this will be close to 0)
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2) Missing gender in RPDB (expect this will be close to 0)
3) Listed as living kidney donor more than once in TGLN dataset
4) Donor id = recip id or don_ikn=recip_ikn;

this is either in i) Trillium sources OR ii) when linked to RPDB (note:
appreciate this will remove the rare donor who develops ESRD and then
requires a transplant; guarding against possibility out-of-province donor,
etc. received services under recipient OHIP number).
5)

≥ 1 dialysis code from Appendix A (CIHI or OHIP code) from July 1 st,
1991 to 4 months after index date (rationale: this is being done to exclude
any recipient who has been miscoded as a living kidney donor; appreciate
this will remove any donor who required dialysis within 4 months of
donation – a very rare event).

6) Missing date of nephrectomy (missing

LIVING_DONORS_ENC.TX_DATE; expect this to be 0 as this was used
to construct dataset)
7) Date of death in RPDB is before index date
8) Date of death in RPDB < 4 months AFTER index date (rationale: this is

being done to exclude any deceased kidney donor who has been miscoded
as a living kidney donor. Appreciate this exclusion will result in “immortal
time” for anyone left in the analysis (i.e. no chance of death between index
date and four months after donation; rate of death is so exceedingly rare
this is not an issue).
9)

Date of Last Contact (DOLC) is < 4 months AFTER index date (rationale:
this is being done to exclude any out of province living kidney donors; by
convention it would also result in the exclusion of any deaths in 4 months after
donation, but this exclusion is being applied after the death exclusion above. By
applying this exclusion we are restricting the analysis to those individuals who
have ≥ 1 Ontario health care contact ≥ 4 months after donation).

10) Age <18 at index date
11) Age > 75 at index date

12) Pregnant at the time of index date (defined by evidence of ≥ 1 birth code, in 2
months prior to index date to 6 months after index date; birth codes presented in
Appendix B)
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13) Evidence of kidney stones with surgical intervention prior to the index date
and 7 days after index date (codes presented in Appendix D)

14) Evidence of other hospital encounters for kidney stones prior to the index
date and 7 days after index date (codes presented in Appendix E)

Exclusion
criteria for
CONTROLS
(in order)
(See Table 1a
and 1b)

See Appendix C for control exclusion criteria codes, and “Outline of Analysis
Plan” section for description of method to select control subjects.
Data cleaning steps
Exclude if:
1) Invalid IKN
2) Missing gender in RPDB
3) Missing date of birth in RPDB
4) Date of death in RPDB before July 12, 1992
(1st date of transplant in TGLN database)

5) Age <18 on March 31, 2009
6) Age >75 on January 1, 1992
*ASSIGN INDEX DATE*
Exclude if any of the following:
(from July 1991, up to but not including the index date)

7) Date of death in RPDB is before randomly assigned index date
8) Date of death in RPDB is less than 4 months AFTER index date
(rationale: same exclusion as kidney donors).

9) Age<18 on index date
10) Age >75 on index date
11) Date of Last Contact (DOLC) is less than 4 months AFTER index date
(rationale: same exclusion as kidney donors).
12) Zero or > 4 physician visits in 2 years prior to index date (No matter how many
physicians an individual sees on a given day, or the amount of codes that a physician bills for
on a given day, this is still only counted as one visit. Physician visits defined by spec variable
in the OHIP data – any spec that corresponds to a ‘physician’ (column C, physician “yes” in
excel sheet attached).
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specialty codes.xls

Exclude if any of the following (from July 1991, up to and including the index
date):
13) Diabetes (if date of onset of condition in ODD is before or equal to index date)
14) Hypertension (if date of onset of condition in OHD is before or equal to index date)
15) Cancer
16) Cardiovascular disease
17) Any prior cardiovascular procedure
18) Pulmonary disease
19) Liver disease
20) Systemic lupus erythematosus
21) Rheumatoid arthritis
22) HIV
23) Listed in TGLN as a kidney donor or recipient (control_ikn=don_ikn OR
receipt_ikn from July 1991 to index date)

24) Genitourinary disease
25) Nephrectomy
26) Any prior renal biopsy
27) Exclude if ≥ 1 dialysis code from Appendix A (CIHI or OHIP code) from July
1st, 1991 to 4 months after index date

28) Exclude if have ever seen a nephrologist in consultation:
A consultation is identified by OHIP code A135, billed by a
nephrologist on either an outpatient or inpatient visit, where a nephrologist
is defined as a physician who had both a) and b) anytime during the study
accrual window [window is July 1,1991 to March 31,2009].
a. billed an A135 code ≥50 times during the accrual period (can be same
patient)
b. billed renal dialysis code ≥50 times during accrual period [any OHIP
fee code in Appendix A under category “Hemodialysis”, “Peritoneal
Dialysis” or “Other”, but not “Continuous Renal Replacement
Therapy”; note: can be same patient]

Ensures that controls are extremely healthy in regards to renal function,
specifically.
Exclude if any of the following:
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29) Pregnant at the time of index date (defined by evidence of ≥ 1 birth code, in 2
months prior to index date to 6 months after index date; birth codes presented in
Appendix B)

30) Gestational diabetes prior to index date
31) Pre-eclampsia prior to index date

32) Evidence of kidney stones with surgical intervention prior to the index date
and 7 days after index date:

33) Evidence of other hospital encounter for kidney stones prior to index date and
7 days after index date

Time frame definitions
Accrual Window

Max Follow-up Date

Look-back Window
Observation Window

Index date

Donors:Index
Date date
of donation in TGLN (TX_DATE)
Controls: Matched to donors (see “Matching Variables” section)

Accrual window

July 1, 1992 to March 31, 2009

Look-back window
Max follow-up

Variable look-back window to July 1991 for all subjects to ascertain exclusion
criteria
March 31, 2012 for all subjects

Observation

Observation window terminates when the first of the following censoring
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window
termination

events occurs:
1.
March 31, 2012 (end of the study)
2.
Emigration: For patients who haven’t died prior to end of study (March
31, 2012), if time between Date of Last Contact (DOLC, ICES variable) and
end of study (March 31, 2012) is >3 years, censor at 1 year after DOLC
3.
Death

Variable definitions
Exposure
Baseline
Characteristics
(see Table 2a and
2b)

Living kidney donation, defined by entry in TGLN as a donor.
Observed at time of index date:
Record mean, median, categorical number (%) for the following variables in Table 2a:

1.
Year of index date (report as calendar year)
2.
Age at index date
3.
Gender (Female, N (%))
4.
Income quintile, for missing impute as 3 (median income) for purposes
of matching
5.
Residency status, rural or urban (Report only categorical number, (%));
for ‘missing’, code this as urban
Look back 1 year from index date:
6.
Health care use
[Physicians and non-physicians should be defined using OHIP billing – spec
data]
Non-physician health care professional visits (defined below; if multiple
codes on a single day only count once (%). No difference is expected in the
numbers for donors and controls.
Physician visits (divided into categories, any spec that corresponds to a
‘physician’ (column C, physician “yes” in previously attached excel sheet; if
more than one physician visit on a single day only count once) by the number
of visits) (%). Donors are expected to have more physician visits than
controls.
Code
49
50
51
53
54
55
56
58

Non-Physician Visits (definition for current study)
DENTAL SURGERY (dentistry)
ORAL SURGERY (dentistry)
ORTHODONTICS (dentistry)
PERIODONTICS (dentistry)
ORAL PATHOLOGY (dentistry)
ENDODONTICS (dentistry)
OPTOMETRISTS
CHIROPODISTS
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70
71
80
81

CHIROPRACTOR
ORAL RADIOLOGY (dentistry)
PROSTHODONTICS (dentistry)
PHYSIOTHERAPY (HOME)
PHYSIOTHERAPY (HOME/OFFICE)

Observed at end of follow-up:
7.
Age at last follow-up
Donor characteristics only (Table 2b: These data come from TGLN
database):
8.
9.

Matching
Variables

Donor relationship to recipient (TGLN variable Relationship)
Method of nephrectomy (TGLN variable D_SURG_TYPE)

Match 10 non-donor controls to each donor based on the following five (5)
variables, in order:
1.
Index date (±6 months)
2.
Gender
3.
Age (±2 years)
4.
Income quintile (same quintile; if ‘missing’, value is ‘3’)
5.
Residential status (same status, rural or urban; if ‘missing’, code as
‘urban’)
NB: If not possible to find 10 controls who meet all criteria, choose the
maximum number of controls who do meet all the criteria. Report number of
controls achieved in Table 3.
Assign a unique “Group ID” value to each matched group (1 donor, 10
controls)

Primary outcome

Evidence of kidney stone with surgical intervention following the index date
until March 31, 2012 (see Appendix D for codes, use CIHI-DAD, CIHI-SDS,
NACRS-ED).

Note: Participants can have more than one occurrence of a kidney stone with
surgical intervention during follow-up, but such interventions must be
separated by at least 90 days to ensure it is for a new stone or reoccurrence
of a stone.
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Secondary
outcomes

1.
Evidence of hospital encounter for kidney stones following the index
date until March 31, 2012 (Appendix D and E together, use CIHI-DAD, CIHISDS and NACRS-ED)

2.
Time to first kidney stone with surgical intervention following the
index date until March 31, 2012

3.
Time to first hospital encounter for a kidney stone following the index
date until March 31, 2012

Outline of analysis plan
Steps to Identify
Controls Matched
to Donors

1.
Restrict controls to individuals in the RPDB who have a valid IKN,
date of birth, gender and meet first step of inclusion criteria.
2.
Randomly assign an index date (July 1, 1992 – March 31, 2009) to all
eligible individuals in the RPDB. Assign these index dates to match the
distribution in the LKD cohort (TGLN dataset) based on the minimum,
maximum, 25th, 50th and 75th percentile of the index dates in the LKD cohort.
NB: Match the index date distribution after applying inclusion and exclusion
criteria to the LKD cohort.
3.
Apply exclusion criteria to individuals from the RPDB to determine
eligible controls.
4.
Match 10 controls to each donor (see “Matching Variables” section).
5.
Each individual from the RPDB may serve as a control for no more
than one donor.
Record level of matching achieved in Table 3.

Exploratory and

Apply exclusion criteria and identify number of donors and controls
lost (see Tables 1a and 1b).
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Descriptive
Analyses

Provide the frequencies and descriptive characteristics for all baseline
characteristics for both donors and controls (Table 2a and 2b).

Report standardized differences; to calculate standardized difference
see below

Statistics in Medicine
(PS Matching diagnostics, 2009).pdf

Many-to-one
matching diagnostics 2008.pdf


Report % of missing data for each variable (should be no missing data),
impute value of “3” for missing income (matching characteristic), impute
‘urban’ value for missing urban/rural and discuss with team any other values
with high level of missingness.
Report length of follow-up (max, min, mean, median and total person
years) and distribution of censoring events (categorical number) in Table 4.
As well report the number of persons who reached a maximal given year of
follow-up (Table 5).
Report distribution of primary outcome events (categorical number)
in Table 6.
Primary analysis

Secondary analysis

Compare group differences using a negative binomial regression
model to account for sources of statistical non-independence (multiple
kidney stone events in a given individual, as well as the correlational
structure within each matched set)
Report results in Table 7.
Plot Kaplan-Meier (K-M) survival graphs for donors and controls
(see Table 9a and 9b)

Compare group differences using two-sided log-rank test. This test
needs to account for the ‘correlation’ within group_id (see Figure 1 below). In
this analysis patients are censored for death, emigration and end of the followup period (March 31, 2012).

To account for the correlation, the log rank test is stratified by the
match (group_id). This means the log rank statistic is calculated within
matched sets (group_id), and then is combined to get an overall statistic. It is
NOT weighted by the number of matched controls per matched donor (the
way Cox proportional hazard regression would be in this situation).

66

Figure 1. K-M survival curves for primary outcome time-to-first event (kidney stone with
surgical intervention) analysis
Patients censored for death, emigration and end of the follow-up period (March 31, 2012).
Survival here refers to event free survival.
Example (fictional data):

Log-rank (LKDs vs. controls)
(p = XXXX)

Subgroup analyses

Perform subgroup analyses for primary outcome only using interaction terms.
Report results in Table 8.
*Note: Organize the subgroup according to the donor characteristic with
their associated matched controls, and report the associative measure and
upper and lower confidence interval to 3 decimal points. We will then
compute each interaction term separately with summary measures using the
method of Bland and Altman.
Gender
Age, <40 vs. ≥40 at index date
Index date, from July 1992 to December 2001 vs. January 2002 to
March 2009

Sets defined by the ‘donor characteristic’; non-donors in set follow
donors.

Produce estimates of point estimate and 95% confidence interval for
each stratum.

We will calculate test of interaction based on the output of point
estimate, lower CI, and upper CI (Bland and Altman technique, embedded
article below, double click icon to access).

interaction altman
and bland bmj article.pdf
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